Self-collected versus clinician-collected cervical samples for the detection of HPV infections by 14-type DNA and 7-type mRNA tests. 2021

C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
Oncology Department, Hospital General de México "Eduardo Liceaga", Mexico City, Mexico.

BACKGROUND HPV self-sampling has been widely supported by the scientific community following a strong body of literature on the subject. Self-sampling is important in cervical cancer screening as it has been shown to improve participation. It is well documented that HPV-testing has proven superior to cytology with regards to sensitivity in detection of CIN and cancer. The value of self-collected samples is reliant on the quality of the molecular testing performed, as well as the patients' preference in sampling procedure and compliance to follow up on positive test results. Due to the incompatibility of self-samples and cytology, triage of HPV-DNA positives by testing for molecular biomarkers is highly warranted. METHODS Our objective was to compare the detection rate of genital Human Papillomavirus (HPV) infection in self- and clinician-collected samples by a 14-type HPV-DNA test and a 7-type mRNA E6/E7 test. RESULTS Five hundred five women were recruited. Each study participant had two sample collection procedures performed upon the same visit, alternating order in execution of the self-collection or the clinician-taken procedure first or second, 1010 samples in total. HPV-DNA prevalence was 22.8% in self-collected versus 19.2% in clinician-collected samples (P = 0.19). Overexpression of mRNA E6/E7 from 7 HPV types was 7.1 and 6.3%, respectively (P = 0.71). The difference between HPV-DNA and HPV-mRNA positivity rates were statistically significant in both self-collected (22.8% versus 7.1%, P < 0.001) and clinician-collected samples (19.2% versus 6.3%, P < 0.001). Overall agreement between the two collection methods was fair, with a concordance rate of 78.2% (390/505), k = 0.34 (95% CI: 0.25-0.44), P < 0.001, for the HPV-DNA test and 92.5% (467/505), k = 0.40 (95% CI, 0.25-0.56), P < 0.001, for the mRNA test, respectively. 96.8% of the participants reported they felt confident carrying out the self-collection themselves, and 88.8% reported no discomfort at all performing the procedure. CONCLUSIONS This comparative study of two sampling methods reports fair agreement of HPV positivity rates between the self-collected and clinician-collected specimens using Abbott hrHPV and PreTect HPV-Proofer'7 tests. Only one third of HPV-DNA positive women had overexpression of mRNA E6/E7. BACKGROUND ISRCTN77337300 .

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013048 Specimen Handling Procedures for collecting, preserving, and transporting of specimens sufficiently stable to provide accurate and precise results suitable for clinical interpretation. Specimen Collection,Collection, Specimen,Collections, Specimen,Handling, Specimen,Handlings, Specimen,Specimen Collections,Specimen Handlings
D055088 Early Detection of Cancer Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior. Cancer Screening,Cancer Screening Tests,Early Diagnosis of Cancer,Cancer Early Detection,Cancer Early Diagnosis,Cancer Screening Test,Screening Test, Cancer,Screening Tests, Cancer,Screening, Cancer,Test, Cancer Screening,Tests, Cancer Screening
D025202 Molecular Diagnostic Techniques MOLECULAR BIOLOGY techniques used in the diagnosis of disease. Molecular Testing,Molecular Diagnostic Technics,Molecular Diagnostic Testing,Diagnostic Technic, Molecular,Diagnostic Technics, Molecular,Diagnostic Technique, Molecular,Diagnostic Techniques, Molecular,Diagnostic Testing, Molecular,Molecular Diagnostic Technic,Molecular Diagnostic Technique,Technic, Molecular Diagnostic,Technics, Molecular Diagnostic,Technique, Molecular Diagnostic,Techniques, Molecular Diagnostic,Testing, Molecular,Testing, Molecular Diagnostic

Related Publications

C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
February 2019, The Lancet. Oncology,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
July 2006, Gynecologic oncology,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
July 2019, Annals of internal medicine,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
July 2019, Journal of lower genital tract disease,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
January 2022, Journal of gynecologic oncology,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
January 2023, International journal of women's health,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
January 2024, Asian Pacific journal of cancer prevention : APJCP,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
August 2012, Journal of pediatric and adolescent gynecology,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
January 2020, Infectious agents and cancer,
C E Aranda Flores, and G Gomez Gutierrez, and J M Ortiz Leon, and D Cruz Rodriguez, and S W Sørbye
October 2023, Diagnostics (Basel, Switzerland),
Copied contents to your clipboard!